413 results on '"Leszek, Jerzy"'
Search Results
152. Genomics of Dementia:APOE- and CYP2D6-Related Pharmacogenetics.
- Author
-
Cacabelos, Ramón, Martínez, Rocío, Fernández-Novoa, Lucía, Carril, Juan C., Lombardi, Valter, Carrera, Iván, Corzo, Lola, Tellado, Iván, Leszek, Jerzy, McKay, Adam, and Takeda, Masatoshi
- Published
- 2012
- Full Text
- View/download PDF
153. Disturbances of innate immunity in Alzheimer's disease: Possible therapeutic approach
- Author
-
Leszek, Jerzy
- Published
- 2012
- Full Text
- View/download PDF
154. Mechanisms of over-activated innate immune system regulation in autoimmune and neurodegenerative disorders.
- Author
-
Blach-Olszewska, Zofia and Leszek, Jerzy
- Published
- 2007
155. Fenotyp oksydacji i fenotyp acetylacji w chorobie Alzheimera -- doniesienie wstępne.
- Author
-
Milejski, Piotr, Orzechowska-Juzwenko, Krystyna, Niewiński, Przemysław, Hurkacz, Magdalena, Czarnik-Matusewicz, Henryk, Leszek, Jerzy, Rudzik, Jacek, and Grotthus, Bartosz
- Subjects
ACETYLATION ,SPARTEINE ,ALZHEIMER'S patients ,OXIDATION ,PHENOTYPES - Abstract
Copyright of Psychiatria Polska is the property of Editorial Committee of Polish Psychiatric Association and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2007
156. EEG SLEEP PATTERN DURTNG INTERFERON TREATMENT
- Author
-
Jernajczyk Wojciech and Leszek Jerzy
- Subjects
Pharmacology ,medicine.medical_specialty ,Interferon ,business.industry ,medicine ,Pharmacology (medical) ,Neurology (clinical) ,Audiology ,business ,Sleep eeg ,medicine.drug - Published
- 1992
- Full Text
- View/download PDF
157. Higher expressions of macromolecular forms and C-terminal domain of plasma fibronectin more frequently associated with Alzheimer's disease
- Author
-
Leszek, Jerzy and Lemanska, Anna
- Published
- 2011
- Full Text
- View/download PDF
158. Oxidative stress-induced mitochondrial DNA overproliferation and deletion, cellular hypoperfusion and brain hypometabolism in the context of Alzheimer's disease: past, present and future
- Author
-
Aliev, Gjumrakch, Gasiorowski, Kazimierz, Palacios, Hector, Gokhman, Dmitry, Shadlinski, Vagif, Bragin, Valentin, and Leszek, Jerzy
- Published
- 2011
- Full Text
- View/download PDF
159. Oxidative stress-induced mitochondrial failure and brain hypometabolism underlay the pathophysiology of Alzheimer's disease and offer target for treatment: Astonishing effect of melanin and mitochondrial antioxidants
- Author
-
Aliev, Gjumrakch, Palacios, Hector H., Gasimov, Eldar, Gokhman, Dmitry, Leszek, Jerzy, Morales, Ludis, Obrenovich, Mark E., Bragin, Valentin, and Herrera, Arturo Solís
- Published
- 2010
- Full Text
- View/download PDF
160. Targeting oxidative stress-induced brain hypometabolism and brain mitochondrial failure as new and effective strategies for the prevention and treatment of cognitive decline in elderly demented/depressed patients and those with Alzheimer's disease: New scents on the trail?
- Author
-
Aliev, Gjumrakch, Palacios, Hector H., Gasimov, Eldar, Gokhman, Dmitry, Leszek, Jerzy, Obrenovich, Mark E., Bragin, Valentin, and Herrera, Arturo Solís
- Published
- 2010
- Full Text
- View/download PDF
161. Advanced glycation end products a specific biochemical marker for detection of Alzheimer's disease
- Author
-
Leszek, Jerzy W. and Gamian, Andrzej
- Published
- 2010
- Full Text
- View/download PDF
162. The effect of donepezil on the reactions of the innate immune system in the peripheral blood leukocytes of healthy young blood donors
- Author
-
Leszek, Jerzy W., Blach-Olszewska, Zofia, Zaczynska, Ewa, and Siemieniec, Iwona
- Published
- 2009
- Full Text
- View/download PDF
163. Trudności w komunikacji z pacjentem z chorobą Alzheimera.
- Author
-
Leszek, Jerzy
- Published
- 2016
164. Cognitive Decline in Early and Premature Menopause.
- Author
-
Sochocka, Marta, Karska, Julia, Pszczołowska, Magdalena, Ochnik, Michał, Fułek, Michał, Fułek, Katarzyna, Kurpas, Donata, Chojdak-Łukasiewicz, Justyna, Rosner-Tenerowicz, Anna, and Leszek, Jerzy
- Subjects
- *
MENOPAUSE , *PREMATURE menopause , *COGNITION disorders , *MIDDLE age , *MILD cognitive impairment , *HORMONE therapy for menopause , *ALZHEIMER'S disease , *SEX hormones - Abstract
Early and premature menopause, or premature ovarian insufficiency (POI), affects 1% of women under the age of 40 years. This paper reviews the main aspects of early and premature menopause and their impact on cognitive decline. Based on the literature, cognitive complaints are more common near menopause: a phase marked by a decrease in hormone levels, especially estrogen. A premature reduction in estrogen puts women at a higher risk for cardiovascular disease, parkinsonism, depression, osteoporosis, hypertension, weight gain, midlife diabetes, as well as cognitive disorders and dementia, such as Alzheimer's disease (AD). Experimental and epidemiological studies suggest that female sex hormones have long-lasting neuroprotective and anti-aging properties. Estrogens seem to prevent cognitive disorders arising from a cholinergic deficit in women and female animals in middle age premature menopause that affects the central nervous system (CNS) directly and indirectly, both transiently and in the long term, leads to cognitive impairment or even dementia, mainly due to the decrease in estrogen levels and comorbidity with cardiovascular risk factors, autoimmune diseases, and aging. Menopausal hormone therapy from menopause to the age of 60 years may provide a "window of opportunity" to reduce the risk of mild cognitive impairment (MCI) and AD in later life. Women with earlier menopause should be taken care of by various specialists such as gynecologists, endocrinologists, neurologists, and psychiatrists in order to maintain their mental health at the highest possible level. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
165. The Amyloid Cascade Hypothesis in Alzheimer's Disease: Should We Change Our Thinking?
- Author
-
Kurkinen, Markku, Fułek, Michał, Fułek, Katarzyna, Beszłej, Jan Aleksander, Kurpas, Donata, and Leszek, Jerzy
- Subjects
- *
AMYLOID beta-protein , *ALZHEIMER'S disease , *DISEASE risk factors , *GLUTAMATE transporters , *AMYLOID , *PEPTIDES - Abstract
Old age increases the risk of Alzheimer's disease (AD), the most common neurodegenerative disease, a devastating disorder of the human mind and the leading cause of dementia. Worldwide, 50 million people have the disease, and it is estimated that there will be 150 million by 2050. Today, healthcare for AD patients consumes 1% of the global economy. According to the amyloid cascade hypothesis, AD begins in the brain by accumulating and aggregating Aβ peptides and forming β-amyloid fibrils (Aβ42). However, in clinical trials, reducing Aβ peptide production and amyloid formation in the brain did not slow cognitive decline or improve daily life in AD patients. Prevention studies in cognitively unimpaired people at high risk or genetically destined to develop AD also have not slowed cognitive decline. These observations argue against the amyloid hypothesis of AD etiology, its development, and disease mechanisms. Here, we look at other avenues in the research of AD, such as the presenilin hypothesis, synaptic glutamate signaling, and the role of astrocytes and the glutamate transporter EAAT2 in the development of AD. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
166. The progressive nature of concentration camp syndrome in former prisoners of Nazi concentration camps – Not just history, but the important issue of contemporary medicine.
- Author
-
Jabłoński, Robert, Rosińczuk, Joanna, Leszek, Jerzy, Uchmanowicz, Izabella, and Panaszek, Bernard
- Subjects
- *
PSYCHOLOGICAL effects of concentration camps , *DISEASE progression , *PRISON psychology , *HISTORY of medicine , *PSYCHOLOGICAL stress , *SLAVE labor - Abstract
Constant stress, slave labor, tortures, and starvation all affected the health of concentration camp prisoners, contributing to multimorbidities, increased mortality and accelerated development of chronic illnesses, what we have shown in an earlier publication. The interrelated somatic and psychological symptoms gave rise to concentration camp syndrome (KZ-syndrome), which has many features of PTSD, occurring frequently nowadays. The paper attempts at assessing the influence of concentration camp conditions on functional disorders in each system of the human body, occurring in KZ-syndrome, and at demonstrating the progressive nature of the syndrome. A retrospective assessment of the former prisoners' health after 5 and 30 years following their leaving camps was performed based on medical records and surveys. The materials included 250 former prisoners who underwent medical examination in 1950, i.e. 5 years after leaving the camp, of whom 120 former prisoners survived and were examined and surveyed in 1975, i.e. 30 years after leaving the camp. KZ-syndrome was shown to occur in 58.8% of former prisoners 5 years after leaving the camp, and in 77.5% after 30 years (p < 0.001), which confirms the syndrome's chronic and progressive nature. Pathological sequels of internment in concentration camps, in the form of KZ-syndrome, were observed in most former prisoners. Over time, the number of morbidities and the intensity of symptoms increased, which indicates that the syndrome has a chronic and progressive nature. KZ-syndrome is a multi-organ disorder, with numerous chronic comorbidities exacerbating the progression. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
167. Cardiovascular, Pulmonary, and Neuropsychiatric Short- and Long-Term Complications of COVID-19.
- Author
-
Kobusiak-Prokopowicz, Małgorzata, Fułek, Katarzyna, Fułek, Michał, Kaaz, Konrad, Mysiak, Andrzej, Kurpas, Donata, Beszłej, Jan Aleksander, Brzecka, Anna, and Leszek, Jerzy
- Subjects
- *
POST-acute COVID-19 syndrome , *SARS-CoV-2 , *COVID-19 , *COVID-19 pandemic , *CLINICAL deterioration , *SYMPTOMS , *NEUROENDOCRINE cells - Abstract
Beginning with the various strategies of the SARS-CoV-2 virus to invade our bodies and manifest infection, and ending with the recent long COVID, we are witnessing the evolving course of the disease in addition to the pandemic. Given the partially controlled course of the COVID-19 pandemic, the greatest challenge currently lies in managing the short- and long-term complications of COVID-19. We have assembled current knowledge of the broad spectrum of cardiovascular, pulmonary, and neuropsychiatric sequelae following SARS-CoV-2 infection to understand how these clinical manifestations collectively lead to a severe form of the disease. The ultimate goal would be to better understand these complications and find ways to prevent clinical deterioration. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
168. Effect of donepezil on innate antiviral immunity of human leukocytes
- Author
-
Sochocka, Marta, Zaczyńska, Ewa, Leszek, Jerzy, Siemieniec, Iwona, and Błach-Olszewska, Zofia
- Subjects
- *
LEUCOCYTES , *IMMUNITY , *CYTOKINES , *VIRUS diseases - Abstract
Abstract: Background: The effect of donepezil on two mechanisms of innate immunity: leukocyte resistance to viral infection and cytokine production was studied. Methods: The degree of natural resistance of human peripheral blood leukocytes (PBLs) was determined by studying the kinetics of vesicular stomatitis virus (VSV) replication. A titer of 0–1 log TCID50 indicated complete resistance, 2–3 log partial resistance, and >4 lack of resistance. Cytokine levels were determined with use of ELISA test. NFκB activation was assayed by immunocytochemical staining. Results: Preliminary study of VSV replication in the PBLs of Alzheimer''s disease patients showed a high sensitivity to infection, except of PBL those under donepezil therapy. The PBL resistance stimulated us to study the effect of donepezil on innate immunity. Donepezil inhibited VSV replication in the leukocytes of healthy blood donors but influence on infection in L929 and A549 cells was not shown. The effect was dose dependent and individually differentiated. The production of TNFα and IFNs was reduced in infected leukocytes in a dose-dependent manner in the PBLs of the healthy blood donors and of AD patients. NFκB activation was also reduced by donepezil. Conclusions: Donepezil regulate two mechanisms of innate immunity of leukocytes: resistance to viruses and cytokine production. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
169. Design and Development of Nanomaterial-Based Drug Carriers to Overcome the Blood–Brain Barrier by Using Different Transport Mechanisms.
- Author
-
Song, Jisu, Lu, Chao, Leszek, Jerzy, and Zhang, Jin
- Subjects
- *
BLOOD-brain barrier , *DRUG delivery systems , *DRUG carriers , *PHYSIOLOGY , *DRUG development , *BIOLOGICAL transport , *CENTRAL nervous system - Abstract
Central nervous system (CNS) diseases are the leading causes of death and disabilities in the world. It is quite challenging to treat CNS diseases efficiently because of the blood–brain barrier (BBB). It is a physical barrier with tight junction proteins and high selectivity to limit the substance transportation between the blood and neural tissues. Thus, it is important to understand BBB transport mechanisms for developing novel drug carriers to overcome the BBB. This paper introduces the structure of the BBB and its physiological transport mechanisms. Meanwhile, different strategies for crossing the BBB by using nanomaterial-based drug carriers are reviewed, including carrier-mediated, adsorptive-mediated, and receptor-mediated transcytosis. Since the viral-induced CNS diseases are associated with BBB breakdown, various neurotropic viruses and their mechanisms on BBB disruption are reviewed and discussed, which are considered as an alternative solution to overcome the BBB. Therefore, most recent studies on virus-mimicking nanocarriers for drug delivery to cross the BBB are also reviewed and discussed. On the other hand, the routes of administration of drug-loaded nanocarriers to the CNS have been reviewed. In sum, this paper reviews and discusses various strategies and routes of nano-formulated drug delivery systems across the BBB to the brain, which will contribute to the advanced diagnosis and treatment of CNS diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
170. Diet and Alzheimer's dementia – Nutritional approach to modulate inflammation.
- Author
-
Szczechowiak, Katarzyna, Diniz, Breno S., and Leszek, Jerzy
- Subjects
- *
BUTYRATES , *PROBIOTICS , *ALZHEIMER'S disease - Abstract
Alzheimer's disease (AD) is the most common neurodegenerative disease causing dementia in the elderly population. Due to the fact that there is still no cure for Alzheimer's dementia and available treatment strategies bring only symptomatic benefits, there is a pressing demand for other effective strategies such as diet. Since the inflammation hypothesis gained considerable significance in the AD pathogenesis, elucidating the modulatory role of dietary factors on inflammation may help to prevent, delay the onset and slow the progression of AD. Current evidence clearly shows that synergistic action of combined supplementation and complex dietary patterns provides stronger benefits than any single component considered separately. Recent studies reveal the growing importance of novel factors such as dietary advanced glycation end products (d-AGE), gut microbiota, butyrate and vitamin D 3 on inflammatory processes in AD. This paper summarizes the available evidence of pro- and anti-inflammatory activity of some dietary components including fatty acids, vitamins, flavonoids, polyphenols, probiotics and d-AGE, and their potential for AD prevention and treatment. • We found a compendium of anti-inflammatory nutritional substances which can counteract inflammation in Alzheimer's disease. • Combined supplementation and complex dietary patterns provide stronger anti-inflammatory benefits than any single component • Overconsumption of foods rich in d-AGEs, saturated fats and meat, have a pro-inflammatory influence on AD patients brains [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
171. Münchausen syndrome as an unusual cause of pseudo-resistant hypertension: a case report.
- Author
-
Kobusiak-Prokopowicz, Małgorzata, Marciniak, Anna, Tokarczyk, Bogdan, Kała, Maria, Leszek, Jerzy, and Mysiak, Andrzej
- Abstract
Münchausen syndrome can be characterized by simulated illness, pathological lying and wandering from place to place (the patient typically presents to numerous hospitals). Individuals with elevated blood pressure due to non-adherence to medication have the so-called pseudo-resistant hypertension. A 45-year-old woman was admitted to hospital on an emergency basis because of a hypertensive crisis. Despite combination antihypertensive treatment, normalization of blood pressure was not achieved and a device to produce a therapeutic arteriovenous fistula was implanted. After the procedure, a significant increase in pulmonary artery pressure was observed and closure of the fistula was performed by implantation of the stent graft. The suspicion was raised that the patient had not been taking her prescribed medications. Therefore, blood samples were taken and the serum was analyzed for presence of the prescribed drugs (atorvastatin, bisoprolol, chlorthalidone, clonidine, doxazosin, furosemide, nitrendipine, oxazepam and valsartan). The results confirmed suspected failure of the patient to take the prescribed medications. Münchausen syndrome is usually first suspected when inexplicable laboratory test results are noted. To our knowledge, this is the first reported case of Münchausen syndrome with pseudo-resistant hypertension leading to the implantation of a device to produce a therapeutic arteriovenous fistula. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
172. The diabetic brain and cognition.
- Author
-
Riederer, Peter, Korczyn, Amos, Ali, Sameh, Bajenaru, Ovidiu, Choi, Mun, Chopp, Michael, Dermanovic-Dobrota, Vesna, Grünblatt, Edna, Jellinger, Kurt, Kamal, Mohammad, Kamal, Warda, Leszek, Jerzy, Sheldrick-Michel, Tanja, Mushtaq, Gohar, Meglic, Bernard, Natovich, Rachel, Pirtosek, Zvezdan, Rakusa, Martin, Salkovic-Petrisic, Melita, and Schmidt, Reinhold
- Subjects
- *
PEOPLE with diabetes , *COGNITION in old age , *ALZHEIMER'S disease , *VASCULAR dementia , *MILD cognitive impairment , *COGNITION disorder risk factors - Abstract
The prevalence of both Alzheimer's disease (AD) and vascular dementia (VaD) is increasing with the aging of the population. Studies from the last several years have shown that people with diabetes have an increased risk for dementia and cognitive impairment. Therefore, the authors of this consensus review tried to elaborate on the role of diabetes, especially diabetes type 2 (T2DM) in both AD and VaD. Based on the clinical and experimental work of scientists from 18 countries participating in the International Congress on Vascular Disorders and on literature search using PUBMED, it can be concluded that T2DM is a risk factor for both, AD and VaD, based on a pathology of glucose utilization. This pathology is the consequence of a disturbance of insulin-related mechanisms leading to brain insulin resistance. Although the underlying pathological mechanisms for AD and VaD are different in many aspects, the contribution of T2DM and insulin resistant brain state (IRBS) to cerebrovascular disturbances in both disorders cannot be neglected. Therefore, early diagnosis of metabolic parameters including those relevant for T2DM is required. Moreover, it is possible that therapeutic options utilized today for diabetes treatment may also have an effect on the risk for dementia. T2DM/IRBS contribute to pathological processes in AD and VaD. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
173. Alterations in molecular status of plasma fibronectin associated with aging of normal human individuals.
- Author
-
Lemańska-Perek, Anna, Pupek, Małgorzata, Polańska, Bożena, Leszek, Jerzy, and Kątnik-Prastowska, Iwona
- Subjects
- *
FIBRONECTINS , *BLOOD plasma , *AGING , *IMMUNOBLOTTING , *MONOCLONAL antibodies , *TISSUE remodeling - Abstract
Abstract: Objectives: Senescence, progressive deterioration of many bodily functions might be associated with age-dependent alterations of plasma fibronectin (FN) molecular status (i.e., domain, glycotope, and molecular form expressions). Design and methods: FN molecular status was analyzed in 127 plasma samples of healthy individuals in groups of newborns, and subjects aged 3–14, 15–39, 41–59, and 60–82years by FN-ELISA, lectin-FN-ELISA, and immunoblotting using a set of domain-specific monoclonal antibodies, specific lectins, and monoclonal antibody to FN, respectively. Results: During the first four decades of human life the levels of cell-binding-, carboxyl-terminal-, collagen-, heparin-, and fibrin-domains of plasma FN gradually increased. In subjects aged up to 82years the cell-binding and carboxyl-terminal FN domain concentrations did not change, while the heparin, fibrin, and collagen domains significantly increased. The relative reactivity of plasma FN with Maackia amurensis lectin, specific to α2,3-linked sialic acid, significantly decreased after birth, reaching a stable level in the subsequent life period, whereas with Sambucus nigra lectin, specific to α2,6-linked sialic acid, it significantly decreased in the 60–82year old group. Moreover, the appearance of 280-kDa and 320-kDa FN bands, absent in young and mature healthy individuals, was found in the groups of 41–59 and 60–82year olds. Conclusions: The alterations of FN molecular status throughout growth, maturation and senescence might be associated not only with disturbances in the balance of FN production rate and degradation, but concomitantly with conformational rearrangements of FN and its engagement in age-related vascular remodeling processes. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
174. The influence of donepezil and EGb 761 on the innate immunity of human leukocytes: Effect on the NF-κB system
- Author
-
Sochocka, Marta, Zaczyńska, Ewa, Taboł, Agnieszka, Czarny, Anna, Leszek, Jerzy, and Sobczyński, Maciej
- Subjects
- *
ALZHEIMER'S disease , *VIRAL replication , *NF-kappa B , *NATURAL immunity , *LEUCOCYTES , *GINKGO , *SYNTHETIC drugs , *IMMUNOCYTOCHEMISTRY - Abstract
Abstract: Ginkgo biloba special extract EGb 761 and donepezil are drugs used in Alzheimer therapy. The influence of donepezil and EGb 761 on two mechanisms of innate immunity, natural antiviral resistance of human leukocytes ex vivo and NF-κB activation, was studied. Correlation between the innate immunity of leukocytes and NF-κB activation was investigated. The effect of the two drugs on resistance of human leukocytes to vesicular stomatitis virus (VSV) infection was also assessed. Two groups of healthy blood donors (n=30) were distinguished: one with resistant leukocytes (n=15) and one (n=15) with leukocytes sensitive to VSV. The degree of natural resistance of human peripheral blood leukocytes (PBLs) was determined by studying the kinetics of VSV replication. NF-κB activation was assayed by immunocytochemical staining. Efficiency of donepezil and EGb 761 was determined by a special regression model. The toxicity of the preparations to PBLs and the cell lines L929 and A549 and their effect on the different viruses was established. Results showed that donepezil used in concentrations of 10–50μg/ml and EGb761 of 25–100μg/ml stimulated resistance of human leukocytes. At the same concentrations both preparations decreased activation of transcriptional factor NF-κB. Correlation between innate immunity of PBLs and NF-κB activation was observed. Comparison of the effects of these two drugs showed that EGb 761 is more effective in stimulating leukocyte resistance. Donepezil and EGb 761 regulated innate immunity of human leukocytes by stimulating resistance and modulating NF-κB activation. The natural drug was more efficient in stimulating innate antiviral immunity of human leukocytes. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
175. Evaluation of CSF-Chlamydia pneumoniae, CSF-tau, and CSF-Abeta42 in Alzheimer’s disease and vascular dementia.
- Author
-
Paradowski, Bogusław, Jaremko, Malgorzata, Dobosz, Tadeusz, Leszek, Jerzy, and Noga, Leszek
- Subjects
- *
CHLAMYDOPHILA pneumoniae , *CHLAMYDIA infections , *ALZHEIMER'S disease , *PRESENILE dementia , *VASCULAR dementia , *DEMENTIA , *CEREBROSPINAL fluid , *BODY fluids - Abstract
The potential role of microbiological factors such as Chlamydia pneumoniae (ChP) in the pathogenesis of neurodegenerative disorders, including Alzheimer’s disease (AD) and vascular dementia (VD), has been suggested, but the correctness of this hypothesis still needs to be tested. In this study the appearance of ChP in the cerebrospinal fluid (CSF) of 57 AD and 21 VD patients and in 47 controls (CG) as well as the influence of ChP on the levels of tau protein and Aβ42 were investigated. The frequency of ChP occurrence in the AD patient group (43.9%) was significantly higher ( p < 0.001) than in the control group (10.6%). In the case of VD patients, 9.5% of this group was positive for ChP. The presence of ChP DNA in the CSF of patients with AD significantly increases the occurrence of this disease (odds ratio = 7.21). Cerebrospinal fluid Aβ42 levels were significantly lower in patients with AD than in the CG ( p < 0.001). Cerebrospinal tau protein was significantly higher in AD vs. CG ( p = 0.007). However, no relationships between the presence of the bacterium in CSF and the level of either tau or Aβ42 protein were observed. In conclusion, we may suspect that testing for the presence of ChP in CSF, along with the tau and Aβ42 markers, may be used in the clinic diagnosis of AD. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
176. New therapeutic targeting of Alzheimer's disease with the potential use of proline-rich polypeptide complex to modulate an innate immune response - preliminary study.
- Author
-
Sochocka, Marta, Ochnik, Michał, Sobczyński, Maciej, Siemieniec, Iwona, Orzechowska, Beata, Naporowski, Piotr, and Leszek, Jerzy
- Subjects
- *
ALZHEIMER'S disease , *IMMUNOLOGIC diseases , *IMMUNE response , *VESICULAR stomatitis , *ENZYME-linked immunosorbent assay - Abstract
Background: The lack of effective treatment for Alzheimer's disease (AD) stems mainly from the incomplete understanding of AD causes. Neuroinflammation has emerged as an important component of AD pathology, and a vast number of experimental and clinical data indicated a crucial role for the activation of the innate immune system in disease promotion and symptom progression.Methods: Clinical examinations of AD patients in a different stage of disease severity in correlation with the measurement of two innate immune reactions, i.e., peripheral blood leukocyte (PBLs) resistance to viral infection (vesicular stomatitis virus, VSV) ex vivo, and cytokines: TNF-α, IFN-γ, IL-1β, and IL-10, production with enzyme-linked immunosorbent assay (ELISA), have been investigated during this preliminary study before and after 4 weeks of oral treatment with dietary supplement proline-rich polypeptide complex (PRP) (120 μg of PRP/day). The potential effect of PRP on the distribution of PBLs' subpopulations has been specified.Results: We have found a deficiency in innate immune response in AD patients. It was demonstrated for the first time that the degree of PBLs resistance to VSV infection was closely related to the stage of clinical severity of AD. Our study showed significant differences in cytokine production which pointed that in AD patients innate immune mechanisms are impaired. Administration of PRP to our patients increased innate immune response of PBLs and declined pro- and anti-inflammatory cytokine production, thus subduing the excessively developed inflammatory response, especially among patients with high severity of AD. PRP did not exhibit a pro-proliferative activity. It was showed, however, significant influence of PRP on the distribution of PBLs' subpopulations.Conclusion: The findings mentioned above might be crucial in the context of potential application of immunomodulatory therapy in AD patients and indicated PRP as a potential target for future treatments in neuroinflammatory diseases like AD. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
177. Correction to: Molecular cross‑talk between long COVID‑19 and Alzheimer's disease.
- Author
-
Pszczołowska M, Walczak K, Miśków W, Antosz K, Batko J, Karska J, and Leszek J
- Published
- 2024
- Full Text
- View/download PDF
178. Dendrimers-Novel Therapeutic Approaches for Alzheimer's Disease.
- Author
-
Mroziak M, Kozłowski G, Kołodziejczyk W, Pszczołowska M, Walczak K, Beszłej JA, and Leszek J
- Abstract
Dendrimers are covalently bonded globular nanostructures that may be used in the treatment of Alzheimer's disease (AD). Nowadays, AD therapies are focused on improving cognitive functioning and not causal treatment. However, this may change with the use of dendrimers, which are being investigated as a drug-delivery system or as a drug per se. With their ability to inhibit amyloid formation and their anti-tau properties, they are a promising therapeutic option for AD patients. Studies have shown that dendrimers may inhibit amyloid formation in at least two ways: by blocking fibril growth and by breaking already existing fibrils. Neurofibrillary tangles (NFTs) are abnormal filaments built by tau proteins that can be accumulated in the cell, which leads to the loss of cytoskeletal microtubules and tubulin-associated proteins. Cationic phosphorus dendrimers, with their anti-tau properties, can induce the aggregation of tau into amorphous structures. Drug delivery to mitochondria is difficult due to poor transport across biological barriers, such as the inner mitochondrial membrane, which is highly negatively polarized. Dendrimers may be potential nanocarriers and increase mitochondria targeting. Another considered use of dendrimers in AD treatment is as a drug-delivery system, for example, carbamazepine (CBZ) or tacrine. They can also be used to transport siRNA into neuronal tissue and to carry antioxidants and anti-inflammatory drugs to act protectively on the nervous system.
- Published
- 2024
- Full Text
- View/download PDF
179. Correlation between Alzheimer's Disease and Gastrointestinal Tract Disorders.
- Author
-
Kuźniar J, Kozubek P, Czaja M, and Leszek J
- Subjects
- Humans, Brain-Gut Axis physiology, Helicobacter Infections complications, Helicobacter Infections microbiology, Periodontitis microbiology, Gastrointestinal Tract microbiology, Gastrointestinal Tract metabolism, Helicobacter pylori, Inflammatory Bowel Diseases microbiology, Inflammatory Bowel Diseases metabolism, Brain metabolism, Alzheimer Disease microbiology, Gastrointestinal Microbiome, Gastrointestinal Diseases microbiology
- Abstract
Alzheimer's disease is the most common cause of dementia globally. The pathogenesis is multifactorial and includes deposition of amyloid-β in the central nervous system, presence of intraneuronal neurofibrillary tangles and a decreased amount of synapses. It remains uncertain what causes the progression of the disease. Nowadays, it is suggested that the brain is connected to the gastrointestinal tract, especially the enteric nervous system and gut microbiome. Studies have found a positive association between AD and gastrointestinal diseases such as periodontitis, Helicobacter pylori infection, inflammatory bowel disease and microbiome disorders. H. pylori and its metabolites can enter the CNS via the oropharyngeal olfactory pathway and may predispose to the onset and progression of AD. Periodontitis may cause systemic inflammation of low severity with high levels of pro-inflammatory cytokines and neutrophils. Moreover, lipopolysaccharide from oral bacteria accompanies beta-amyloid in plaques that form in the brain. Increased intestinal permeability in IBS leads to neuronal inflammation from transference. Chronic inflammation may lead to beta-amyloid plaque formation in the intestinal tract that spreads to the brain via the vagus nerve. The microbiome plays an important role in many bodily functions, such as nutrient absorption and vitamin production, but it is also an important factor in the development of many diseases, including Alzheimer's disease. Both the quantity and diversity of the microbiome change significantly in patients with AD and even in people in the preclinical stage of the disease, when symptoms are not yet present. The microbiome influences the functioning of the central nervous system through, among other things, the microbiota-gut-brain axis. Given the involvement of the microbiome in the pathogenesis of AD, antibiotic therapy, probiotics and prebiotics, and faecal transplantation are being considered as possible therapeutic options.
- Published
- 2024
- Full Text
- View/download PDF
180. The Effects of Transcranial Direct Current Stimulation (tDCS) in HIV Patients-A Review.
- Author
-
Chmiel J, Kurpas D, Rybakowski F, and Leszek J
- Abstract
Introduction : HIV is a severe and incurable disease that has a devastating impact worldwide. It affects the immune system and negatively affects the nervous system, leading to various cognitive and behavioral problems. Scientists are actively exploring different therapeutic approaches to combat these issues. One promising method is transcranial direct current stimulation (tDCS), a non-invasive technique that stimulates the brain. Methods : This review aims to examine how tDCS can help HIV patients. Searches were conducted in the Pubmed/Medline, Research Gate, and Cochrane databases. Results : The literature search resulted in six articles focusing on the effects of tDCS on cognitive and behavioral measures in people with HIV. In some cases, tDCS showed positive improvements in the measures assessed, improving executive functions, depression, attention, reaction time, psychomotor speed, speed of processing, verbal learning and memory, and cognitive functioning. Furthermore, the stimulation was safe with no severe side effects. However, the included studies were of low quality, had small sample sizes, and did not use any relevant biomarkers that would help to understand the mechanisms of action of tDCS in HIV. Conclusions : tDCS may help patients with HIV; however, due to the limited number of studies and the diversity of protocols used, caution should be exercised when recommending this treatment option in clinical settings. More high-quality research, preferably involving neurophysiological and neuroimaging measurements, is necessary to better understand how tDCS works in individuals with HIV.
- Published
- 2024
- Full Text
- View/download PDF
181. Molecular cross-talk between long COVID-19 and Alzheimer's disease.
- Author
-
Pszczołowska M, Walczak K, Misków W, Antosz K, Batko J, Karska J, and Leszek J
- Subjects
- Humans, SARS-CoV-2, Post-Acute COVID-19 Syndrome, Amyloid beta-Peptides, Chronic Disease, Alzheimer Disease metabolism, COVID-19
- Abstract
The long COVID (coronavirus disease), a multisystemic condition following severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, is one of the widespread problems. Some of its symptoms affect the nervous system and resemble symptoms of Alzheimer's disease (AD)-a neurodegenerative condition caused by the accumulation of amyloid beta and hyperphosphorylation of tau proteins. Multiple studies have found dependence between these two conditions. Patients with Alzheimer's disease have a greater risk of SARS-CoV-2 infection due to increased levels of angiotensin-converting enzyme 2 (ACE2), and the infection itself promotes amyloid beta generation which enhances the risk of AD. Also, the molecular pathways are alike-misregulations in folate-mediated one-carbon metabolism, a deficit of Cq10, and disease-associated microglia. Medical imaging in both of these diseases shows a decrease in the volume of gray matter, global brain size reduction, and hypometabolism in the parahippocampal gyrus, thalamus, and cingulate cortex. In some studies, a similar approach to applied medication can be seen, including the use of amino adamantanes and phenolic compounds of rosemary. The significance of these connections and their possible application in medical practice still needs further study but there is a possibility that they will help to better understand long COVID., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
182. Mitochondrial disorders leading to Alzheimer's disease-perspectives of diagnosis and treatment.
- Author
-
Pszczołowska M, Walczak K, Miśków W, Mroziak M, Chojdak-Łukasiewicz J, and Leszek J
- Subjects
- Mice, Animals, Amyloid beta-Peptides metabolism, Mitochondria metabolism, Antioxidants, Alzheimer Disease diagnosis, Alzheimer Disease etiology, Alzheimer Disease therapy, Mitochondrial Diseases metabolism
- Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder and the most common cause of dementia globally. The pathogenesis of AD remains still unclear. The three main features of AD are extracellular deposits of amyloid beta (Aβ) plaque, accumulation of abnormal formation hyper-phosphorylated tau protein, and neuronal loss. Mitochondrial impairment plays an important role in the pathogenesis of AD. There are problems with decreased activity of multiple complexes, disturbed mitochondrial fusion, and fission or formation of reactive oxygen species (ROS). Moreover, mitochondrial transport is impaired in AD. Mouse models in many research show disruptions in anterograde and retrograde transport. Both mitochondrial transportation and network impairment have a huge impact on synapse loss and, as a result, cognitive impairment. One of the very serious problems in AD is also disruption of insulin signaling which impairs mitochondrial Aβ removal.Discovering precise mechanisms leading to AD enables us to find new treatment possibilities. Recent studies indicate the positive influence of metformin or antioxidants such as MitoQ, SS-31, SkQ, MitoApo, MitoTEMPO, and MitoVitE on mitochondrial functioning and hence prevent cognitive decline. Impairments in mitochondrial fission may be treated with mitochondrial division inhibitor-1 or ceramide., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
183. Association between Female Reproductive Factors and Risk of Dementia.
- Author
-
Pszczołowska M, Walczak K, Miśków W, Mroziak M, Kozłowski G, Beszłej JA, and Leszek J
- Abstract
Women have an over 50% greater risk of dementia than men, which is a main topic of much research. This review aims to investigate the impact of a woman's reproductive history on dementia risk. The consequences of stillbirth are long-term health and psychosocial problems for women. Because of the awareness of an endangered pregnancy, many parents experience deep anxiety and stress in subsequent pregnancies. There are contradictory conclusions from research about abortion and the risk of dementia correlation. When it comes to the late age of first birth, which is said to be above 35 years old, it was observed that older mothers have a decreased risk of dementia compared to those who gave birth in their 20s; however, being a child of the older mother is connected with a higher risk of developing dementia. Using hormonal contraception can result in decreased risk of dementia as estrogen stimulates microglia-related Aβ removal and reduces tau hyperphosphorylation. The influence of postmenopausal hormonal therapy and the duration of the reproductive period on developing dementia remains unclear. Although female disorders like endometriosis and polycystic ovary syndrome are reported to increase the risk of dementia, the research on this topic is very limited, especially when it comes to endometriosis, and needs further investigation. Interestingly, there is no conclusion on whether hypertensive disorders of pregnancy increase the risk of dementia, but most articles seem to confirm this theory.
- Published
- 2024
- Full Text
- View/download PDF
184. The Effectiveness of Transcranial Direct Current Stimulation (tDCS) in Binge Eating Disorder (BED)-Review and Insight into the Mechanisms of Action.
- Author
-
Chmiel J, Kurpas D, Rybakowski F, and Leszek J
- Subjects
- Female, Humans, Craving physiology, Dorsolateral Prefrontal Cortex, Prefrontal Cortex, Treatment Outcome, Male, Binge-Eating Disorder therapy, Binge-Eating Disorder psychology, Transcranial Direct Current Stimulation methods
- Abstract
Introduction: Binge eating disorder (BED) is the most common eating disorder among those contributing to the development of obesity, and thus acts as a significant burden on the lives and health of patients. It is characterized by complex neurobiology, which includes changes in brain activity and neurotransmitter secretion. Existing treatments are moderately effective, and so the search for new therapies that are effective and safe is ongoing., Aim and Methods: This review examines the use of transcranial direct current stimulation (tDCS) in the treatment of binge eating disorder. Searches were conducted on the PubMed/Medline, Research Gate, and Cochrane databases., Results: Six studies were found that matched the review topic. All of them used the anodal stimulation of the right dorsolateral prefrontal cortex (DLPFC) in BED patients. tDCS proved effective in reducing food cravings, the desire to binge eat, the number of binging episodes, and food intake. It also improved the outcomes of inhibitory control and the treatment of eating disorder psychopathology. The potential mechanisms of action of tDCS in BED are explained, limitations in current research are outlined, and recommendations for future research are provided., Conclusions: Preliminary evidence suggests that the anodal application of tDCS to the right DLPFC reduces the symptoms of BED. However, caution should be exercised in the broader use of tDCS in this context due to the small number of studies performed and the small number of patients included. Future studies should incorporate neuroimaging and neurophysiological measurements to elucidate the potential mechanisms of action of tDCS in BED.
- Published
- 2024
- Full Text
- View/download PDF
185. Chronic Traumatic Encephalopathy as the Course of Alzheimer's Disease.
- Author
-
Pszczołowska M, Walczak K, Miśków W, Antosz K, Batko J, Kurpas D, and Leszek J
- Subjects
- Humans, tau Proteins metabolism, Amyloid beta-Peptides metabolism, Animals, Blood-Brain Barrier metabolism, Blood-Brain Barrier pathology, Alzheimer Disease complications, Alzheimer Disease pathology, Alzheimer Disease etiology, Chronic Traumatic Encephalopathy pathology, Chronic Traumatic Encephalopathy complications
- Abstract
This editorial investigates chronic traumatic encephalopathy (CTE) as a course of Alzheimer's disease (AD). CTE is a debilitating neurodegenerative disease that is the result of repeated mild traumatic brain injury (TBI). Many epidemiological studies show that experiencing a TBI in early or middle life is associated with an increased risk of dementia later in life. Chronic traumatic encephalopathy (CTE) and Alzheimer's disease (AD) present a series of similar neuropathological features that were investigated in this work like recombinant tau into filaments or the accumulation and aggregation of Aβ protein. However, these two conditions differ from each other in brain-blood barrier damage. The purpose of this review was to evaluate information about CTE and AD from various articles, focusing especially on new therapeutic possibilities for the improvement in cognitive skills.
- Published
- 2024
- Full Text
- View/download PDF
186. The Effectiveness of Mindfulness in the Treatment of Methamphetamine Addiction Symptoms: Does Neuroplasticity Play a Role?
- Author
-
Chmiel J, Malinowska A, Rybakowski F, and Leszek J
- Abstract
Introduction: Methamphetamine is a highly stimulating psychoactive drug that causes life-threatening addictions and affects millions of people around the world. Its effects on the brain are complex and include disturbances in the neurotransmitter systems and neurotoxicity. There are several known treatment methods, but their effectiveness is moderate. It must be emphasised that no drugs have been approved for treatment. For this reason, there is an urgent need to develop new, effective, and safe treatments for methamphetamine. One of the potential treatments is mindfulness meditation. In recent years, this technique has been researched extensively in the context of many neurological and psychiatric disorders., Methods: This review explores the use of mindfulness in the treatment of methamphetamine addiction. Searches were conducted in the PubMed/Medline, Research Gate, and Cochrane databases., Results: Ten studies were identified that used mindfulness-based interventions in the treatment of methamphetamine addiction. The results show that mindfulness is an effective form of reducing hunger, risk of relapses, stress indicators, depression, and aggression, alone or in combination with transcranial direct current stimulation (tDCS). Mindfulness also improved the cognitive function in addicts. The included studies used only behavioural measures. The potential mechanisms of mindfulness in addiction were explained, and it was proposed that it can induce neuroplasticity, alleviating the symptoms of addiction., Conclusions: Evidence from the studies suggest that mindfulness may be an effective treatment option for methamphetamine addiction, used alone or in combination with tDCS. However, further high-quality research is required to establish the role of this treatment option in this field. The use of neuroimaging and neurophysiological measures is fundamental to understand the mechanisms of mindfulness.
- Published
- 2024
- Full Text
- View/download PDF
187. Chaperones-A New Class of Potential Therapeutic Targets in Alzheimer's Disease.
- Author
-
Batko J, Antosz K, Miśków W, Pszczołowska M, Walczak K, and Leszek J
- Subjects
- Humans, Molecular Chaperones metabolism, HSP90 Heat-Shock Proteins metabolism, HSP70 Heat-Shock Proteins, Amyloid beta-Peptides, Alzheimer Disease metabolism
- Abstract
The review describes correlations between impaired functioning of chaperones and co-chaperones in Alzheimer's disease (AD) pathogenesis. The study aims to highlight significant lines of research in this field. Chaperones like Hsp90 or Hsp70 are critical agents in regulating cell homeostasis. Due to some conditions, like aging, their activity is damaged, resulting in β-amyloid and tau aggregation. This leads to the development of neurocognitive impairment. Dysregulation of co-chaperones is one of the causes of this condition. Disorders in the functioning of molecules like PP5, Cdc37, CacyBP/SIPTRAP1, CHIP protein, FKBP52, or STIP1 play a key role in AD pathogenesis. PP5, Cdc37, CacyBP/SIPTRAP1, and FKBP52 are Hsp90 co-chaperones. CHIP protein is a co-chaperone that switches Hsp70/Hsp90 complexes, and STIP1 binds to Hsp70. Recognition of precise processes allows for the invention of effective treatment methods. Potential drugs may either reduce tau levels or inhibit tau accumulation and aggregation. Some substances neuroprotect from Aβ toxicity. Further studies on chaperones and co-chaperones are required to understand the fundamental tenets of this topic more entirely and improve the prevention and treatment of AD.
- Published
- 2024
- Full Text
- View/download PDF
188. Artificial light and neurodegeneration: does light pollution impact the development of Alzheimer's disease?
- Author
-
Karska J, Kowalski S, Gładka A, Brzecka A, Sochocka M, Kurpas D, Beszłej JA, and Leszek J
- Subjects
- Humans, Light Pollution, Circadian Rhythm physiology, Alzheimer Disease etiology
- Abstract
Two multidimensional problems of recent times - Alzheimer's disease and light pollution - seem to be more interrelated than previously expected. A series of studies in years explore the pathogenesis and the course of Alzheimer's disease, yet the mechanisms underlying this pathology remain not fully discovered and understood. Artificial lights which accompany civilization on a daily basis appear to have more detrimental effects on both environment and human health than previously anticipated. Circadian rhythm is affected by inappropriate lighting conditions in particular. The consequences are dysregulation of the sleep-wake cycle, gene expression, neuronal restructuring, brain's electricity, blood flow, metabolites' turnover, and gut microbiota as well. All these phenomena may contribute to neurodegeneration and consequently Alzheimer's disease. There is an increasing number of research underlining the complexity of the correlation between light pollution and Alzheimer's disease; however, additional studies to enhance the key tenets are required for a better understanding of this relationship., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
189. Endocytosis and Alzheimer's disease.
- Author
-
Zadka Ł, Sochocka M, Hachiya N, Chojdak-Łukasiewicz J, Dzięgiel P, Piasecki E, and Leszek J
- Subjects
- Humans, Amyloid beta-Protein Precursor genetics, Amyloid beta-Protein Precursor metabolism, Amyloid beta-Peptides metabolism, Neurofibrillary Tangles metabolism, Neurofibrillary Tangles pathology, Endocytosis, Alzheimer Disease genetics
- Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and is the most common cause of dementia. The pathogenesis of AD still remains unclear, including two main hypotheses: amyloid cascade and tau hyperphosphorylation. The hallmark neuropathological changes of AD are extracellular deposits of amyloid-β (Aβ) plaques and intracellular neurofibrillary tangles (NFTs). Endocytosis plays an important role in a number of cellular processes including communication with the extracellular environment, nutrient uptake, and signaling by the cell surface receptors. Based on the results of genetic and biochemical studies, there is a link between neuronal endosomal function and AD pathology. Taking this into account, we can state that in the results of previous research, endolysosomal abnormality is an important cause of neuronal lesions in the brain. Endocytosis is a central pathway involved in the regulation of the degradation of amyloidogenic components. The results of the studies suggest that a correlation between alteration in the endocytosis process and associated protein expression progresses AD. In this article, we discuss the current knowledge about endosomal abnormalities in AD., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
190. EEG in Down Syndrome-A Review and Insights into Potential Neural Mechanisms.
- Author
-
Chmiel J, Rybakowski F, and Leszek J
- Abstract
Introduction : Down syndrome (DS) stands out as one of the most prevalent genetic disorders, imposing a significant burden on both society and the healthcare system. Scientists are making efforts to understand the neural mechanisms behind the pathophysiology of this disorder. Among the valuable methods for studying these mechanisms is electroencephalography (EEG), a non-invasive technique that measures the brain's electrical activity, characterised by its excellent temporal resolution. This review aims to consolidate studies examining EEG usage in individuals with DS. The objective was to identify shared elements of disrupted EEG activity and, crucially, to elucidate the neural mechanisms underpinning these deviations. Searches were conducted on Pubmed/Medline, Research Gate, and Cochrane databases. Results : The literature search yielded 17 relevant articles. Despite the significant time span, small sample size, and overall heterogeneity of the included studies, three common features of aberrant EEG activity in people with DS were found. Potential mechanisms for this altered activity were delineated. Conclusions : The studies included in this review show altered EEG activity in people with DS compared to the control group. To bolster these current findings, future investigations with larger sample sizes are imperative., Competing Interests: The authors declare no conflicts of interest.
- Published
- 2024
- Full Text
- View/download PDF
191. Effect of Transcranial Direct Current Stimulation (tDCS) on Depression in Parkinson's Disease-A Narrative Review.
- Author
-
Chmiel J, Rybakowski F, and Leszek J
- Abstract
Introduction: Depression is the most prevalent comorbid neuropsychiatric condition in individuals with Parkinson's disease (PD), and its underlying mechanisms are not yet fully understood. Current treatment methods are characterised by moderate effectiveness and possible side effects, prompting the search for new non-invasive and safe treatment methods., Methods: This narrative review explores the use of transcranial direct current stimulation (tDCS) in the treatment of depression in PD, based on neuropsychological measures. Searches were conducted in the PubMed/Medline, Research Gate, and Cochrane databases., Results: Nine relevant studies were identified, where depression scores served as either primary or secondary outcomes. Stimulation protocols displayed heterogeneity, especially concerning choice of stimulation site. Patient samples were also heterogeneous. The majority of the studies incorporated anodal stimulation targeting the left dorsolateral prefrontal cortex (DLPFC). The results revealed a reduction in depression scores among PD patients following tDCS. Potential mechanisms through which tDCS may alleviate depression in PD were discussed and recommendations for future research were made., Conclusions: Preliminary evidence suggests that tDCS applied anodally to the left DLPFC reduces depression scores in people with PD; however, due to the heterogeneity of the studies analysed, the use of tDCS in this field should be approached with caution and warrants further validation and confirmation.
- Published
- 2024
- Full Text
- View/download PDF
192. Correlations between Dementia and Loneliness.
- Author
-
Karska J, Pszczołowska M, Gładka A, and Leszek J
- Subjects
- Humans, Loneliness, Brain, COVID-19, Cognitive Behavioral Therapy, Dementia epidemiology
- Abstract
This review describes associations between dementia and loneliness on the neurobiological and epidemiological levels according to the recent body of literature. The aim of this study was to highlight major lines of research in this field. Sociocognitive skills and social interactions present complex interdependencies with dementia which may be explained by two theories. According to the first one, not sufficiently engaging in social or cognitive activities results in brain atrophy. The second one claims that brain neurogenesis and synaptic density are being increased by social connections. The relationship between loneliness and dementia could be mediated by sensory loss, including hearing and visual impairment, as well as depression and psychotic symptoms. Loneliness itself might cause a depletion in sensory and cognitive stimulation which results in a decrease in neural reserve. Certain changes in the structures of the brain caused by loneliness were found in imaging examination. Loneliness appears to be a crucial risk factor for dementia in recent times due to the modern lifestyle and consequences of the outbreak of COVID-19. Additional studies are required to understand more completely the key tenets of this topic and therefore to improve the prevention and treatment of dementia.
- Published
- 2023
- Full Text
- View/download PDF
193. The Effect of Transcranial Direct Current Stimulation (tDCS) on Anorexia Nervosa: A Narrative Review.
- Author
-
Chmiel J, Gladka A, and Leszek J
- Subjects
- Humans, Brain diagnostic imaging, Brain physiology, Feeding Behavior physiology, Transcranial Magnetic Stimulation methods, Prefrontal Cortex physiology, Transcranial Direct Current Stimulation methods, Anorexia Nervosa therapy
- Abstract
(1) Introduction: Anorexia nervosa (AN) is a severe, debilitating disease with high incidence and high mortality. The methods of treatment used so far are moderately effective. Evidence from neuroimaging studies helps to design modern methods of therapy. One of them is transcranial direct current stimulation (tDCS), a non-invasive brain neuromodulation technique. (2) Methods: The purpose of this narrative review is to bring together all studies investigating the use of tDCS in the treatment of AN and to evaluate its effect and efficiency. Searches were conducted in the Pubmed/Medline, Research Gate, and Cochrane databases. (3) Results: The literature search resulted in five articles. These studies provide preliminary evidence that tDCS has the potential to alter eating behaviour, body weight, and food intake. Additionally, tDCS reduced symptoms of depression. Throughout all trials, stimulation targeted the left dorsolateral prefrontal cortex (DLPFC). Although the number of studies included is limited, attempts were made to elucidate the potential mechanisms underlying tDCS action in individuals with AN. Recommendations for future tDCS research in AN were issued. (4) Conclusions: The included studies have shown that tDCS stimulation of the left DLPFC has a positive effect on AN clinical symptoms and may improve them, as measured by various assessment measures. It is important to conduct more in-depth research on the potential benefits of using tDCS for treating AN. This should entail well-designed studies incorporating advanced neuroimaging techniques, such as fMRI. The aim is to gain a better understanding of how tDCS works in AN.
- Published
- 2023
- Full Text
- View/download PDF
194. The Effect of Transcranial Direct Current Stimulation (tDCS) on Cocaine Addiction: A Narrative Review.
- Author
-
Chmiel J, Chojdak-Łukasiewicz J, and Leszek J
- Abstract
Cocaine addiction is a significant problem worldwide. The development of addiction involves a reward system, which consists of certain brain regions like the ventral tegmental area, nucleus accumbens, and prefrontal cortex. Currently, there are no approved medications for treating cocaine dependence, so researchers are actively searching for effective treatments that can impact the brain. One potential treatment under investigation is transcranial direct current stimulation (tDCS), a non-invasive method of stimulating the brain to modulate its activity. In this review, we explore the use of tDCS in treating cocaine addiction. We found nine relevant articles via a literature search, and the results indicate that applying tDCS to the right dorsolateral prefrontal cortex (DLPFC) holds promise for reducing drug cravings in individuals with cocaine addiction. The review also discusses the possible mechanisms by which tDCS works and provides recommendations for future research in this field.
- Published
- 2023
- Full Text
- View/download PDF
195. The Lymphatic System In The Brain Clearance Mechanisms - New Therapeutic Perspectives For Alzheimer's Disease.
- Author
-
Chachaj A, Gąsiorowski K, Szuba A, Sieradzki A, and Leszek J
- Subjects
- Humans, Brain metabolism, Lymphatic System metabolism, Lymphatic System pathology, Extracellular Fluid metabolism, Alzheimer Disease metabolism, Glymphatic System metabolism
- Abstract
Alzheimer's disease (AD) is the most common cause of dementia worldwide. Pathological deposits of neurotoxic proteins within the brain, such as amyloid-ß and hyperphosphorylated tau tangles, are the prominent features in AD. According to recent studies, the newly discovered brain lymphatic system was demonstrated to be crucial in the clearance of metabolic macromolecules from the brain. Meningeal lymphatic vessels located in the dura mater drain the fluid, macromolecules, and immune cells from cerebrospinal fluid (CSF) and transport them, as lymph, to the deep cervical lymph nodes. The lymphatic system provides the perivascular exchange of CSF with interstitial fluid (ISF) and ensures the homeostasis of neuronal interstitial space. In this review, we aim to summarize recent findings on the role of the lymphatic system in AD pathophysiology and discuss possible therapeutic perspectives, targeting the lymphatic clearance mechanisms within the brain., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2023
- Full Text
- View/download PDF
196. Sex Differences in Innate Immune Response of Peripheral Blood Leukocytes of Alzheimer's Disease Patients.
- Author
-
Sochocka M, Ochnik M, Sobczyński M, Orzechowska B, and Leszek J
- Subjects
- Cytokines, Female, Humans, Immunity, Innate, Leukocytes, Male, Sex Characteristics, Tumor Necrosis Factor-alpha, Alzheimer Disease, Interleukin-10
- Abstract
Neurodegenerative disorders, including Alzheimer's disease (AD), are associated with a disruption of normal immune function that could potentially impact the brain. In AD sex and gender have been noted as relevant to disease prevalence or clinical manifestation. It is suggested that disease progression could vary as a result of the different inflammation state among males and females. The objective was to investigate sex-dependent difference in innate immunity of AD patients and healthy, age-matched controls. The level of innate immunity was measured with test based on peripheral blood leukocytes (PBLs) resistance to viral infection (vesicular stomatitis virus, VSV) ex vivo. Cytokine: TNF-α, IFN-γ, IL-1β, IL-10 production by uninfected and VSV-infected PBLs ex vivo with enzyme-linked immunosorbent assay were examined. In contrast to controls, women with AD exhibit lower average level of innate immunity than AD men. The mean level of TNF-α, IL-10 and IL-1β was higher in AD men than in AD women whereas such changes were not observed among controls. The level of IFN-γ was higher in AD than in controls. PBLs from AD did not increase IFN-γ production after viral infection in contrast to controls. Leukocytes from women with AD exhibited a weaker response to viral infection and much less cytokine production compared to men with AD. It is important to consider sex as a biological variable in AD as it shows promises to advance our understanding of mechanisms of AD pathology and may be the basis for future treatment of AD., (© 2022. L. Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland.)
- Published
- 2022
- Full Text
- View/download PDF
197. Ginkgo Biloba Leaf Extract Improves an Innate Immune Response of Peripheral Blood Leukocytes of Alzheimer's Disease Patients.
- Author
-
Sochocka M, Ochnik M, Sobczyński M, Gębura K, Zambrowicz A, Naporowski P, and Leszek J
- Subjects
- Female, Humans, Interleukin-10, Interleukin-15, Leukocytes, Tumor Necrosis Factor-alpha, Alzheimer Disease immunology, Ginkgo biloba chemistry, Immunity, Innate, Plant Extracts pharmacology, Plant Extracts therapeutic use
- Abstract
Background: One of the main features of Alzheimer's disease (AD) pathology is failure in innate immune response and chronic inflammation. Lack of effective AD treatment means that more attention is paid to alternative therapy and drugs of natural origin, such as extract of Ginkgo biloba (EGb). The purpose of this study was to investigate the effect of EGb on the mechanisms of innate immune response of peripheral blood leukocytes (PBLs) in AD patients., Methods: In AD patients and healthy-age matched controls, the effect of EGb on two of innate immune reactions, i.e., PBLs resistance to viral infection ex vivo and production of cytokines, namely TNF-α, IFN-γ, IL-1β, IL-10, IL-15, and IFN-α, were investigated. The influence of EGb on inflammatory-associated genes expression that regulate innate immune response to viral infection and cytokine production, namely IRF-3, IRF-7, tetherin, SOCS1, SOCS3, NFKB1, p65, and MxA was also examined., Results: A beneficial effect of EGb especially in AD women was observed. EGb decreased production of TNF-α, IFN-γ, and IL-10 and increased IL-15 and IL-1β. The effect was more pronouncement in AD group. EGb also downregulated expression of investigated genes., Conclusions: EGb may have an advantageous properties for health management in elderly and AD sufferers but especially in women with AD. Improving peripheral innate immune cells' activity by adding EGb as accompanying treatment in AD may be, in the long term, a good course to modify the disease progression.
- Published
- 2022
- Full Text
- View/download PDF
198. Current and Near-Future Treatment of Alzheimer's Disease.
- Author
-
Gąsiorowski K, Brokos JB, Sochocka M, Ochnik M, Chojdak-Łukasiewicz J, Zajączkowska K, Fułek M, and Leszek J
- Subjects
- Amyloid beta-Peptides metabolism, Brain metabolism, Humans, Neurons metabolism, Oxidative Stress, Alzheimer Disease drug therapy, Alzheimer Disease metabolism
- Abstract
Recent findings have improved our understanding of the multifactorial nature of AD. While in early asymptomatic stages of AD, increased amyloid-β synthesis and tau hyperphosphorylation play a key role, while in the latter stages of the disease, numerous dysfunctions of homeostatic mechanisms in neurons, glial cells, and cerebrovascular endothelium determine the rate of progression of clinical symptoms. The main driving forces of advanced neurodegeneration include increased inflammatory reactions in neurons and glial cells, oxidative stress, deficiencies in neurotrophic growth and regenerative capacity of neurons, brain insulin resistance with disturbed metabolism in neurons, or reduction of the activity of the Wnt-β catenin pathway, which should integrate the homeostatic mechanisms of brain tissue. In order to more effectively inhibit the progress of neurodegeneration, combination therapies consisting of drugs that rectify several above-mentioned dysfunctions should be used. It should be noted that many widely-used drugs from various pharmacological groups, "in addition" to the main therapeutic indications, have a beneficial effect on neurodegeneration and may be introduced into clinical practice in combination therapy of AD. There is hope that complex treatment will effectively inhibit the progression of AD and turn it into a slowly progressing chronic disease. Moreover, as the mechanisms of bidirectional communication between the brain and microbiota are better understood, it is expected that these pathways will be harnessed to provide novel methods to enhance health and treat AD., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2022
- Full Text
- View/download PDF
199. Antisense oligonucleotides for Alzheimer's disease therapy: from the mRNA to miRNA paradigm.
- Author
-
Grabowska-Pyrzewicz W, Want A, Leszek J, and Wojda U
- Subjects
- Alzheimer Disease drug therapy, Brain Chemistry, Gene Expression Regulation drug effects, Gene Regulatory Networks drug effects, Humans, MicroRNAs antagonists & inhibitors, Molecular Targeted Therapy, RNA, Messenger antagonists & inhibitors, Alzheimer Disease genetics, MicroRNAs genetics, Oligonucleotides, Antisense pharmacology, RNA, Messenger genetics
- Abstract
Alzheimer's disease (AD) represents a particular therapeutic challenge because its aetiology is very complex, with dynamic progression from preclinical to clinical stages. Several potential therapeutic targets and strategies were tested for AD, in over 2000 clinical trials, but no disease-modifying therapy exists. This failure indicates that AD, as a multifactorial disease, may require multi-targeted approaches and the delivery of therapeutic molecules to the right place and at the right disease stage. Opportunities to meet the challenges of AD therapy appear to come from recent progress in knowledge and methodological advances in the design, synthesis, and targeting of brain mRNA and microRNA with synthetic antisense oligonucleotides (ASOs). Several types of ASOs allow the utilisation of different mechanisms of posttranscriptional regulation and offer enhanced effects over alternative therapeutics. This article reviews ASO-based approaches and targets in preclinical and clinical trials for AD, and presents the future perspective on ASO therapies for AD., Competing Interests: Declaration of Competing Interest UW is the coauthor on a patent concerning use of circulating miRNAs as diagnostic biomarkers for early Alzheimer's disease (EP3449009), (Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
200. Inverse Correlation Between Alzheimer's Disease and Cancer: Short Overview.
- Author
-
Zabłocka A, Kazana W, Sochocka M, Stańczykiewicz B, Janusz M, Leszek J, and Orzechowska B
- Subjects
- Humans, Risk Factors, Signal Transduction physiology, Alzheimer Disease metabolism, Inflammation metabolism, Neoplasms metabolism
- Abstract
The negative association between Alzheimer's disease (AD) and cancer suggests that susceptibility to one disease may protect against the other. When biological mechanisms of AD and cancer and relationship between them are understood, the unsolved problem of both diseases which still touches the growing human population could be overcome. Actual information about biological mechanisms and common risk factors such as chronic inflammation, age-related metabolic deregulation, and family history is presented here. Common signaling pathways, e.g., p53, Wnt, role of Pin1, and microRNA, are discussed as well. Much attention is also paid to the potential impact of chronic viral, bacterial, and fungal infections that are responsible for the inflammatory pathway in AD and also play a key role to cancer development. New data about common mechanisms in etiopathology of cancer and neurological diseases suggests new therapeutic strategies. Among them, the use of nilotinib, tyrosine kinase inhibitor, protein kinase C, and bexarotene is the most promising., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.